STAAR Surgical Company (STAA)
NASDAQ: STAA · Real-Time Price · USD
17.65
-0.15 (-0.82%)
Mar 31, 2025, 9:45 AM EDT - Market open

Company Description

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye.

The company provides implantable Collamer lens product family (ICLs) and laser-based procedures, such as LASIK to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.

It serves its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.

The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally.

STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.

STAAR Surgical Company
STAAR Surgical Company logo
Country United States
Founded 1982
Industry Medical Instruments & Supplies
Sector Healthcare
Employees 1,157
CEO Stephen Farrell

Contact Details

Address:
25510 Commercentre Drive
Lake Forest, California 92630
United States
Phone 626 303 7902
Website staar.com

Stock Details

Ticker Symbol STAA
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000718937
CUSIP Number 852312305
ISIN Number US8523123052
Employer ID 95-3797439
SIC Code 3851

Key Executives

Name Position
Stephen C. Farrell CFA Chief Executive Officer and Lead Director
Warren Foust President and Chief Operating Officer
Dr. Scott D. Barnes M.D. Chief Medical Officer
Thomas G. Frinzi Advisor
Deborah J. Andrews Interim Chief Financial Officer
Brian Moore Vice President of Investor Relations and Corporate Development
Nathaniel B. Sisitsky Esq. Senior Vice President, General Counsel and Corporate Secretary
Nancy Sabin Chief Marketing Officer
James Francese Senior Vice President of Commercial Operations - North America and APAC
Dr. Magda Michna Ph.D. Chief Development Officer and Chief Clinical, Regulatory and Medical Affairs Officer

Latest SEC Filings

Date Type Title
Mar 28, 2025 SCHEDULE 13G Filing
Mar 18, 2025 8-K Current Report
Mar 3, 2025 SCHEDULE 13D/A Filing
Feb 26, 2025 8-K Current Report
Feb 21, 2025 10-K Annual Report
Feb 11, 2025 8-K Current Report
Feb 5, 2025 SCHEDULE 13G/A Filing
Jan 13, 2025 8-K Current Report
Nov 12, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Oct 31, 2024 8-K/A [Amend] Current report